IL10 and familial pancreatic carcinoma: PBMCs from 7 patients with pancreatic cancer and 2 patients with benign pancreatic disease were peptide-stimulated in the presence of anti-IL-10 and anti-IL-10 receptor blocking antibodies (added to the cultures on day 1 and 4).